Researchers at the Francis Crick Institute and Vividion Therapeutics have developed a new class of chemical compounds that selectively block a key molecular interaction responsible for driving tumor growth in a broad range of cancers. Their findings, published in the journal Science , detail how certain small molecules disrupt the interaction between the RAS protein and PI3Kα, providing a new pathway for treating RAS-driven tumors and HER2-positive cancers, without adverse effects.

“Given the RAS gene is mutated across a wide range of cancers, we’ve been exploring how to stop it interacting with cell growth pathways for many years, but side effects have held back the development of treatments,” said senior author Julian Downward, PhD, principal group leader at the Crick. “Our coll

See Full Page